Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0600

+16.5%

Nov 26 3:10 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: NTTG	6/25/2012 8:55:07 AM
	1 Recommendation of 13111

Nice report in Lancet online on dabrafenib vs dicarbazine for patients with pre-treated III/IV BRAF positive patients (Hauschild et al, 2012), data was presented at ASCO this year, now in press, nice. Dabrafenib increased progression free survival from 2.7 to 5.1 months. Not sure how this would compare to the exclusive local control paradigm that PVCT now seems headed to (bystander effect relegated to a secondary end point?), but good news for melanoma patients. I wonder...locally injected PV-10 vs systemic Tx....what would that data look like?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next